investiment.io
Esperion Therapeutics, Inc.
$2.3
0 (0.03%)
Esperion Therapeutics, Inc.
$2.3
0 (0.03%)
ESPR Price Chart
| Basic | |
|---|---|
| Market Cap | $422.94M |
| Price | $2.23 |
| 52 Week Range | 1.58-3.94 |
| Beta | 0.95 |
| Margins | |
| Gross Profit Margin | 81.57% |
| Operating Profit Margin | 5.57% |
| Net Profit Margin | -29.37% |
| Valuation (TTM) | |
| P/E Ratio | -5.18 |
| Price to Sales Ratio | 1.54 |
| Price to Book Ratio | -1.21 |
| PEG Ratio | -0.20 |
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Full-Time Employees
240
Website
IPO Date
2013-06-26T00:00:00.000Z
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Phone
734 887 3903
Address
3891 Ranchero Drive, Ann Arbor, MI, 48108, US
CIK
0001434868